Infusion related reactions in patients receiving 30-minute BRIUMVI infusions were all mild (Grade 1) and resolved completely Data also demonstrate…
During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50…
HLI is one of the most established, global longevity science companies and committed to accelerating living to 100+ years of…
HACKENSACK, N.J., Sept. 17, 2024 /PRNewswire/ -- On the morning of Wednesday, September 4, 2024, Hackensack Meridian Hackensack University Medical…
Telemedicine pioneer's quality resources and services are recognized by recent recertification FORT MYERS, Fla., Sept. 17, 2024 /PRNewswire/ -- TeleSpecialists,…
Preliminary immunogenicity results demonstrate induction of cancer antigen-specific T-cell responses in 77% of evaluable patients following CVGBM monotherapy84% of immune…
Marks first EMA submission for nipocalimab, an investigational treatment that binds with high affinity and specificity to block FcRn and…
Dr. Lloyd Minor and Prof Sir Menelas Pangalos bring significant scientific expertise and considerable experience in medicine research and developmentCAMBRIDGE,…
LAVAL, QC / ACCESSWIRE / September 11, 2024 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC)…
PARAMUS, N.J., Sept. 10, 2024 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd. (Nippon…
